China and US agree to extend trade tariff truce, says Li
SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently sold shares in the company totaling $45,434, according to a recent SEC filing. The transactions occurred over two days, February 10 and February 11, 2025, under a pre-arranged trading plan. The sales come as GYRE shares have declined nearly 9% over the past week, though the stock maintains a 10% gain over the past year, according to InvestingPro data.
On February 10, Songjiang sold 2,000 shares at a weighted average price of $11.90 per share, with the actual sale prices ranging between $11.72 and $12.12. The following day, an additional 1,878 shares were sold at a weighted average price of $11.52, with sale prices ranging from $11.45 to $11.61. These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024. Want deeper insights into insider trading patterns and their impact? InvestingPro subscribers get access to comprehensive insider transaction analysis and 8 additional key insights about GYRE.
Following these sales, Songjiang retains ownership of 2,875,260 shares, held indirectly by his spouse. Gyre Therapeutics, headquartered in San Diego, operates in the pharmaceutical preparations industry. The company, currently valued at nearly $1 billion, maintains strong liquidity with a current ratio of 3.7, though InvestingPro analysis indicates the stock is trading above its Fair Value.
In other recent news, biotechnology firm Gyre Therapeutics has announced significant changes in its leadership. The company has appointed Ping Zhang as the lead independent director of its Board of Directors, who will also serve on the Nominating and Corporate Governance Committee. Zhang brings a wealth of financial experience to the role, currently holding a position as a Managing Partner at String Capital Management.
Concurrently, there have been alterations at Gyre Therapeutics’ indirectly owned subsidiary, Gyre Pharmaceuticals. Ying Luo has stepped down as Chairman, with Songjiang Ma taking over the role.
These developments come as Gyre Therapeutics continues to focus on the development and commercialization of its drug F351 for MASH-associated fibrosis. Meanwhile, its subsidiary, Gyre Pharmaceuticals, is advancing its pipeline in the People’s Republic of China, including ongoing clinical trials for F351 and the commercialization of ETUARY®, a leading treatment for idiopathic pulmonary fibrosis, which reported net sales of $112.1 million in 2023.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.